International Journal of Medical and Pharmaceutical Research
2021, Volume-2, Issue-1 : 38-42
Original Article
Clinical Outcomes of Proximal Femoral Nail Anti-Rotation in Extracapsular Proximal Femoral Fractures: A Prospective Study
Published
May 18, 2021
Abstract

Background: Extracapsular proximal femoral fractures, predominantly seen in elderly osteoporotic patients, pose a significant treatment challenge due to instability and poor bone quality. Proximal Femoral Nail Anti-Rotation (PFNA) is designed to enhance fixation stability and reduce implant-related complications.

Materials and Methods: A prospective clinical study was conducted on 50 patients with extracapsular proximal femoral fractures (AO/OTA 31-A1 to A3) treated with PFNA between January 2020 to December 2020. Patient demographics, operative parameters, radiological union, and functional outcomes (Harris Hip Score) were recorded. Follow-ups were done at 6 weeks, 3 months, and 6 months. Data were analyzed using descriptive statistics.

Results: The mean age of patients was 68.4 years, with 28 males and 22 females. Mean operative time was 65 ± 12 minutes, and mean intraoperative blood loss was 95 ± 20 mL. Radiological union occurred in an average of 13.4 ± 2.1 weeks. At 6 months, 82% of patients achieved good to excellent outcomes. Complications included varus collapse in 4% and superficial infection in 6%, with no implant failure.

Conclusion: PFNA provides stable fixation, allows early mobilization, and yields excellent union rates in extracapsular proximal femoral fractures, making it a preferred implant in elderly osteoporotic patients.

Recommended Articles
Loading Image...
Volume-2, Issue-1
Citations
515 Views
158 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved